Literature DB >> 11173606

Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Kenneth V Honn1, Amer Aref, Yong Q Chen, Michael L Cher, John D Crissman, Jeffrey D Forman, Xiang Gao, David Grignon, Maha Hussain, Arthur T Porter, Edson J Pontes, Bruce Redman, Wael Sakr, Richard Severson, Dean G Tang, David P Wood.   

Abstract

Diagnostic and prognostic markers for prostatic cancer (PCa) include conventional protein markers (e.g., PAP, PSA, PSMA, PIP, OA-519, Ki-67, PCNA, TF, collagenase, and TIMP 1), angiogenesis indicator (e.g., factor VIII), neuroendocrine differentiation status, adhesion molecules (E-cadherin, integrin), bone matrix degrading products (e.g., ICPT), as well as molecular markers (e.g., PSA, PSMA, p53, 12-LOX, and MSI). Currently, only PSA is used clinically for early diagnosis and monitoring of PCa. The histological differential diagnosis of prostatic adenocarcinoma includes normal tissues such as Cowper's gland, paraganglion tissue and seminal vesicle or ejaculatory duct as well as pathological conditions such as atypical adenomatous hyperplasia, atrophy, basal cell hyperplasia and sclerosing adenosis. A common PCa is characterized by a remarkable heterogeneity in terms of its differentiation, microscopic growth patterns and biological aggressiveness. Most PCa are multifocal with signi ficant variations in tumor grade between anatomically separated tumor foci. The Gleason grading system which recognizes five major grades defined by patterns of neoplastic growth has gained almost uniform acceptance. In predicting the biologic behavior of PCa clinical and pathological stages are used as the major prognostic indicators. Among the cell proliferation and death regulators androgens are critical survival factors for normal prostate epithelial cells as well as for the androgen-dependent human prostatic cancer cells. The androgen ablation has been shown to increase the apoptotic index in prostatic cancer patients and castration also promotes apoptotic death of human prostate carcinoma grown in mice. The progression of PCa, similarly to other malignancies, is a multistep process, accompanied by genetic and epigenetic changes, involving phenomenons as adhesion, invasion and angiogenesis (without prostate specific features).

Entities:  

Year:  1996        PMID: 11173606     DOI: 10.1007/bf02903527

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  234 in total

1.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

2.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

Authors:  J S Horoszewicz; E Kawinski; G P Murphy
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

Review 3.  The biochemistry of programmed cell death.

Authors:  G Kroemer; P Petit; N Zamzami; J L Vayssière; B Mignotte
Journal:  FASEB J       Date:  1995-10       Impact factor: 5.191

Review 4.  Defining apoptosis.

Authors:  D Hockenbery
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

5.  Relative performance characteristics of prostate specific antigen and prostatic specific antigen density for the diagnosis of carcinoma of the prostate.

Authors:  E J Mueller; J Coventry; P M Desmond; E J Zeidman; I M Thompson
Journal:  Urol Oncol       Date:  1995 Mar-Apr       Impact factor: 3.498

6.  Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death.

Authors:  N Kyprianou; H F English; J T Isaacs
Journal:  Prostate       Date:  1988       Impact factor: 4.104

7.  Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.

Authors:  M L Cher; K Chew; W Rosenau; P R Carroll
Journal:  Prostate       Date:  1995-02       Impact factor: 4.104

8.  Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression.

Authors:  V B Lokeshwar; B L Lokeshwar; H T Pham; N L Block
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

9.  12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha.

Authors:  B Liu; R J Maher; Y A Hannun; A T Porter; K V Honn
Journal:  J Natl Cancer Inst       Date:  1994-08-03       Impact factor: 13.506

10.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

Authors:  D L Bluestein; D G Bostwick; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

View more
  4 in total

1.  Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.

Authors:  Sven Gunia; Knut Albrecht; Stefan Koch; Thomas Herrmann; Thorsten Ecke; Volker Loy; Jörg Linke; Michael Siegsmund; Matthias May
Journal:  World J Urol       Date:  2008-04-05       Impact factor: 4.226

2.  Cancer-stromal cell fusion as revealed by fluorescence protein tracking.

Authors:  Ruoxiang Wang; Michael S Lewis; Ji Lyu; Haiyen E Zhau; Stephen J Pandol; Leland W K Chung
Journal:  Prostate       Date:  2019-12-17       Impact factor: 4.104

Review 3.  Molecular pathology of tumor metastasis. I. Predictive pathology.

Authors:  J Tímár; O Csuka; Z Orosz; A Jeney; L Kopper
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

4.  Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.

Authors:  Tomasz Gondek; Mariusz Szajewski; Jarosław Szefel; Ewa Aleksandrowicz-Wrona; Ewa Skrzypczak-Jankun; Jerzy Jankun; Wieslawa Lysiak-Szydlowska
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.